Clinical Trial Update: Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab imaging agents for identifying metastatic lymph nodes in patients with squamous cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• 89Zr-Panitumumab (panitumumab labeled with zirconium-89)
• Panitumumab-IRDye800

Snippet

Sponsor: Andrei Iagaru | Conditions: Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED | Results posted: 2023-05-19